Recce Pharmaceuticals CEO James Graham talked with Proactive about the company’s latest milestone in its global intellectual property strategy — a newly granted patent in China for its synthetic anti-infective candidates, RECCE 327 and RECCE 529.
Graham described the patent as a “significant step in broadening our intellectual property portfolio,” adding that Recce now holds over 40 granted patents across major pharmaceutical markets. The Chinese patent encompasses methods of administration, use for bacterial and viral infections, and methods of manufacture, extending potential market monopolies to 2041.
The Chinese pharmaceutical market, valued at approximately 5.00 billion USD with a 6% compound annual growth rate, presents a major opportunity. Graham noted, “It’s very, very nice to have a market monopoly protection with this new granted patent.”
The patent covers a wide range of infections including acute bacterial skin and skin structure infections (ABSSSI), diabetic foot ulcer infections (studied in both Australia and Indonesia), urinary tract infections, gonorrhoea, and pneumonia. RECCE 327 targets bacterial infections, while RECCE 529 is tailored for antiviral activity, binding specifically to envelope viral cells.
Looking ahead, Recce expects interim data from its Indonesian Phase III trial in Q1 2026. Approval there could open regulatory doors across ASEAN nations. A US FDA Phase III trial announcement is also expected soon.
For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and turn on notifications for future updates.
#ReccePharmaceuticals #ChinaPatent #Antibiotics #Antivirals #BiotechNews #DrugDevelopment #ClinicalTrials #IntellectualProperty #ASEANMarkets #HealthcareInnovation #ProactiveInvestors